An observational study in Neovascular Glaucoma and Type 2 Diabetes, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Qilu Hospital of Shandong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes mellitus (T2DM) without fundus lesions, T2DM patients with diabetic retinopathy (DR), and T2DM patients complicated with both DR and neovascular glaucoma (NVG). The main questions it aims to answer are:
Participants will complete the following tasks:
39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.
Browse Glaucoma, Neovascular studies →Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adults aged 18 years or older of all genders who visit Qilu Hospital, Shandong University. Participants are divided into four groups: healthy volunteers without type 2 diabetes mellitus, patients with type 2 diabetes without fundus lesions, patients with type 2 diabetes combined with diabetic retinopathy, and patients with type 2 diabetic retinopathy complicated by neovascular glaucoma. All subjects have clear consciousness and can cooperate to complete iris OCTA examination, with no contraindications specified in the exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients without type 2 diabetes
Patients with type 2 diabetes but without diabetic retinopathy
Patients with type 2 diabetic retinopathy
Patients with type 2 diabetic retinopathy and neovascular glaucoma
Iris vessel density
Iris vessel density measured by Optical Coherence Tomography Angiography(OCTA)
Time frame: Enrollment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — This study contains sensitive personal medical records and iris imaging data of participants, which involves patient privacy protection. There is no plan to upload individual participant data to public databases or share raw IPD with external researchers. All individual-level identifiable data will not be shared externally to comply with hospital ethics and privacy regulations.
Started May 2026 (actual). Primary completion is estimated for Jul 2026, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University →